此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Exparel Use in Adductor Canal Block After Total Knee Arthroplasty

2022年5月18日 更新者:Chinenye Nwachuku、St. Luke's Hospital, Pennsylvania

Adductor Canal Blocks Using Exparel for Pain Control After Total Knee Arthroplasty

Exparel has been shown to have better pain control compared to previously used infiltration agents, including bupivacaine, while having a minor side effect profile. The purpose of this study is to explore the effectiveness of Exparel (liposomal bupivacaine) in Adductor Canal Blocks for peri-operative pain control following a total knee arthroplasty (TKA) procedure.

研究概览

详细说明

The effectiveness of an Exparel Block (Bupivacaine Liposomal Injectable Suspension) for post-operative pain control has been well studied with encouraging results. At the investigators' institution, Exparel has been approved as a safe and effective option for use in shoulder surgeries and have had encouraging results in adductor canal use for pain control in patients undergoing TKA. Exparel has been shown to have better pain control compared to previously used infiltration agents, including bupivacaine, while having a minor side effect profile. The purpose of this study is to explore the effectiveness of Exparel (liposomal bupivacaine) in Adductor Canal Blocks (ACB) for peri-operative pain control following a total knee arthroplasty (TKA) procedure. Specifically, the investigators look to see if Exparel ACB reduces opioid requirement use post-operatively, reduces pain scores post-operatively, provides earlier mobilization, and decreases length of hospital stay.

研究类型

介入性

注册 (实际的)

100

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Pennsylvania
      • Bethlehem、Pennsylvania、美国、18015
        • St. Luke's University Health Network

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 99年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients were eligible for inclusion if they were undergoing unilateral primary TKA for a diagnosis of knee osteoarthritis and were not undergoing any additional concomitant procedures were.

Exclusion Criteria:

  • Patients were not eligible for our study if they were undergoing revision TKA, if they were undergoing bilateral TKA or concomitant procedures, or if they had an active infection.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Exparel
Liposomal Bupivacaine use as active ingredient in the block
Exparel used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
有源比较器:Control
Ropivacaine use as active ingredient in the block
Ropivacaine used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Hospital Length of Stay
大体时间:Through entire inpatient hospital stay (lasted from 1 day to 1 week)
Inpatient post-operative stay after undergoing TKA procedure
Through entire inpatient hospital stay (lasted from 1 day to 1 week)
Inpatient Opioid Use
大体时间:1 week
Opioid usage during their inpatient post-operative hospital stay
1 week
Numeric Rating Scale (NRS) Pain Score Improvement
大体时间:6 weeks
Measured with Numerical Rating Scale (Range: 0-10, Minimum:0, Maximum:10). Change in NRS Pain Score from pre-operative levels. Positive changes indicate a decrease in pain levels from pre-operative levels.
6 weeks
Outpatient Opioid Use
大体时间:6 weeks
Opioid usage in the immediate post-operative period after hospital discharge
6 weeks
WOMAC Score
大体时间:6 weeks
Western Ontario and McMaster Universities Osteoarthritis Index Patient Subjective Outcome Score (Range: 0-96, Minimum:0, Maximum:96). Subsections include Pain (Range:0-20, Minimum:0, Maximum:20), Stiffness (Range:0-8; Minimum:0, Maximum:8), and Functional Limitation (Range0-68, Minimum:0, Maximum:68). Measured as change in score from baseline levels. Positive scores indicate an improvement in WOMAC scores from pre-operative levels.
6 weeks

次要结果测量

结果测量
措施说明
大体时间
Number of Participants Needing to be Readmitted to the Hospital Secondary to Inadequate Pain Control Post-operatively
大体时间:6 weeks
Rate of needing to be readmitted to the hospital secondary to inadequate pain control post-operatively at any point during the study period.
6 weeks
Number of Participants Needing to be Admitted to an Inpatient Rehabilitation Facility Post-Operatively
大体时间:1 week
Rate of needing to be discharged to an inpatient rehabilitation facility after TKA procedure secondary to inadequate pain control and functional recovery
1 week

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Chinenye Nwachuku, MD、St. Luke's Hospital and Health Network, Pennsylvania

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年6月1日

初级完成 (实际的)

2021年9月15日

研究完成 (实际的)

2021年10月15日

研究注册日期

首次提交

2021年5月25日

首先提交符合 QC 标准的

2021年5月28日

首次发布 (实际的)

2021年6月2日

研究记录更新

最后更新发布 (实际的)

2022年5月20日

上次提交的符合 QC 标准的更新

2022年5月18日

最后验证

2022年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅